Summary Systemic toxicity is usually the dose-limiting factor in cancer chemotherapy. Regional chemotherapy is therefore an attractive strategy in the treatment of liver metastasis. Two ways of regional chemotherapy, hepatic artery infusion (HAI) and isolated liver perfusion (ILP), were compared investigating the difference in toxicity with tissue and biofluid concentrations of mitomycin C (MMC). In wistar derived WAG rats the maximally tolerated dose of mitomycin C via HAI was 1.2 mg kg-'. Body weight measurements after HAI with doses higher than 1.2 mg kg-' suggest both an acute and delayed toxic effect of mitomycin C since the time weight curves were triphasic: a rapid weight loss, a steady state and a second fall in weight phase. These rats died due to systemic toxicity. ILP with 4.8 mg kg-' was associated with no signs of systemic toxicity and only transient mild hepatotoxicity. ILP with 6.0 mg kg-' was fatal mainly due to hepatic toxicity. The four times higher maximally tolerated dose in ILP resulted in a 4-5 times higher peak concentration of mitomycin C in liver tissue, while the plasma concentration remained significantly lower than in the HAI treated rats. In the tumour tissue a 500% higher concentration of mitomycin C was measured in the ILP with 4.8 mg kg-' than in HAI with 1.2 mg kg-' treated rats. We demonstrated that when mitomycin C was administered by ILP a 400% higher dose could be safely administered and resulted in a five times higher tumour tissue concentration. In view of the steep dose-response curve of this alkylating agent this opens new perspectives for the treatment of liver metastasis.
The liver is a major site of metastatic spread of primary colorectal cancer; in as many as 30% of the patients it is also the sole site of initial tumour recurrence . At the time of operation for the primary tumour approximately 5% of patients with colorectal cancer have resectable liver metastases (Foster & Lundy, 1981) . Another 5% will develop resectable metastases confined to the liver after resection of the primary tumour (Foster & Berman, 1977; Adson, 1983) . These patients can be cured by surgery and a 5-year survival rate of about 35% can be achieved (Foster & Lundy, 1981; Adson et al., 1984; August et al., 1985; Iwatsuki et al., 1986) .
Unfortunately, in the majority (75%) of the patients with colorectal cancer metastases confined to the liver, the tumour is not resectable. These patients are eligible for locoregional therapies. The rationale of regional administration of chemotherapy is based on the concept of achieving a high local concentration, while minimising systemic drug levels and, accordingly, reducing dose limiting systemic side-effects (Collins, 1984) . For most chemotherapeutic agents steep dose-response curves can be demonstrated. Therefore, high drug concentrations are important for both sensitive and resistant tumour cells. For resistant cells extremely high exposure is required for adequate cell kill (Slee et al., 1987; Kuppen et al., 1988) .
Exploiting high extraction ratios of the fluoropyrimidines (Chen & Gross, 1980) , currently the most effective drugs in colorectal cancer treatment (Moertel, 1978) , hepatic artery infusion has initially met with some success (Balch et al., 1983) , albeit with considerable dose limiting morbidity (Velde et al., 1987) . In order to obtain cures, isolated liver perfusion (ILP) has been developed in dogs and pigs as a treatment modality that maximises drug concentration in the target organ and at the same time shields the organism from systemic toxicity (Aigner et al., 1982; Skibba et al., 1983; Velde et al., 1986 (Brauw et al., 1988) . In the present study mitomycin C was chosen as the chemotherapeutic drug since the cytotoxic action of mitomycin C is dose related Wallner & Li, 1987) , the cytotoxic action of mitomycin C is non-cell-cycle-phase specific (Iyer & Szybalski, 1964) , and mitomycin C has been reported to be a promising drug against colorectal cancer (Crooke & Bradner, 1976; Doll et al., 1985) . Furthermore, the liver is the major organ in the elimination of mitomycin C (Kerpel-Fronius et al., 1988 (Tjaden et al., 1987) .
Toxicity study First the maximally tolerated dose for HAI was determined by assigning non-tumour-bearing rats to six groups: (1) sham HAI (n = 4); (2) to (5) 1.2 (n = 4), 1.5 (n = 6), 2.4 (n = 4), 3.6 (n = 4) and 4.8 (n = 4) mg MMC kg-' total body weight, respectively. Subsequently non-tumour-bearing rats were assigned to five groups for the ILP toxicity study: (1) (Figure la) . Comparing the 1.5 and 2.4 mg kg-' treated groups, the weight loss during the first phase was about 25 g less in the 1.5 mg kg-' group (57 versus 83 g) and the steady state phase was about 8 days longer (18 versus 10 days); it resulted in significantly (P <0.05) less weight loss from day 17 until death in the 1.5 mg kg-' treated group than in the 2.4 mg kg' treated group. In the 3.6 mg kg-' treated group one rat showed the triphasic pattern but the other three died 10-14 days after treatment after continuous rapid weight loss. Administration of 4.8 mg mitomycin C kg-by HAI was lethal to all rats within 5 days. These rats were losing 1O g body weight per day.
Isolated liver perfusion In contrast to the HAI groups, all rats treated by ILP survived a mitomycin C dose of 4.8 mg kg' (4 x maximally tolerated dose for HAI). These rats treated with high dose mitomycin C showed a dip in their weight between days 9 and 12 (mean values: 58 g after 3.6mg kg-'; 67 after 4.8 mg kg-'). In contrast to the weight loss in HAI treated rats, not all of the weight loss in ILP treated rats was due to mitomycin C toxicity since a sham ILP caused a mean weight loss of 27 g. Results are illustrated in Figure lb. Systemic and hepatic toxicity after HAI or ILP Systemic toxicity During the follow-up, white blood cell count was determined twice in the first week and then once a week together with the electrolytic status (sodium, potassium, urea and creatinine levels in serum).
Three days after administration of mitomycin C by HAI all rats had a significantly decreased white blood cell count (P <0.01) (Figure 2a (1.2hmg kg-' group, 22ngtml'; 4.8 mgkg-' group, 212ng ml-') than in the HAi group (1.2 mg kg-' group, 539 ng ml-'). The liver tissue concentrations of mitomycin C were week until death or to a maximum of 8 weeks following MMC treatment in the isolated liver perfusion setting: * 1.2 (n = 2), 0 3.6 (n = 4) and A 4.8 (n = 6) mg MMC kg-', or via bolus hepatic artery infusion: 0 1.5 (n = 6) mg MMC kg-'. The horizontal lines are the 5% and 95% limits of the normal value range. s.d. (vertical bars) is only indicated if at least one rat had a bilirubin level higher than the 95% limit. The kinetics of hepatic dysfunction seemed similar for serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase.
of the same level in the two 1.2 mg kg-' groups, but were significantly higher in the ILP group with 4.8 mg kg-'. The peak concentration in this 4.8 mg kg-' in ILP group was 3-4 times higher than in the two other groups (ILP 4.8 mg kg-' group, 2147 ng g-'; ILP and HAI 1.2 mg kg' groups, 668 and 671 ng g'l). In eight out of nine cases the mean tissue concentrations were higher in the poorly vascularised tumour (histologically determined, central necrosis present in tumours growing above 3-5 mm) than in liver tissue ( Figure 5 ). This was most pronounced in the ILP with 4.8 mg kg-' group. At t = 5 min the difference was significant (P < 0.05). The peak concentration in the ILP with 4.8 mg kg-' group was three and five times higher than in the ILP and HAI with 1.2 mg kg-' groups respectively (ILP 4.8 mg kg-' group, 3366 ng g-'; ILP and HAI 1.2mg kg-' groups, 1328 and 724 ng g-'). and renal toxicity (Crooke & Bradner, 1976; Gunstream et al., 1983; Chang et al., 1986; Verweij et al., 1987; Cattell, 1985) . In the present study we first evaluated whether a higher dose of mitomycin C could be administered in ILP setting than via HAI and whether dose increase was limited by liver or systemic toxicity. Subsequently, rats were treated with the respective maximally tolerated doses of mitomycin C in ILP and HAI setting and mitomycin C concentrations were measured in liver tissue and in plasma to be able to correlate the differences in toxicity pattern with differences in tissue and plasma concentrations. Furthermore, tumour tissue concentrations were measured to ascertain that the higher doses resulted in higher tumour tissue concentrations. We demonstrated that quite high doses of mitomycin C could be delivered to the liver. All rats treated with 4.8 mg kg-' by ILP survived the 'therapy', while bolus infusion of 1.5 mg kg-' by HAI was already 100% lethal. After ILP treatment with 4.8 mg kg-', SGOT and SGPT were 3-4 times normal during the first two post-operative weeks indicating some liver cell damage. Since the serum potassium levels were within normal range during the blood sample analysis the increased SGPT levels in this study were not due to haemolysis but to liver cell damage. Bilirubin was even more elevated (7-10 times normal) but turned to normal values within 6 weeks. These results indicate that in ILP setting 4.8 mg kg-' (four times the maximally tolerated dose in hepatic artery infusion setting) can still be tolerated. Toxicity is transient and confined to the liver. Five times the maximally tolerated dose in HAI setting (6.0 mg kg-') was 100% lethal within 3 days. Severe liver toxicitity led to multiple infarction and massive hepatocellular necrosis. In a clinical study evaluating intensive mitomycin C therapy and autologous bone marrow transplantation liver toxicity had been observed too. This therapy resulted in veno-occlusive disease of the liver in six out of 29 patients (Lazarus et al., 1982) . In our rat study autopsy did not show any of the characteristic signs of veno-occlusive disease of the liver in any rat.
Three days after ILP all rats had a significant increase in the white blood cell count instead of the significant decrease in white blood cell count that was seen in all rats treated with HAI. These results clearly demonstrate that in the ILP setting liver toxicity rather than systemic toxicity is doselimiting.
When rats were treated with 1.2 mg kg-' via HAI the only signs of toxicity were weight loss during the first 2 weeks after bolus administration of mitomycin C and a white blood cell count dip in the first week. When rats were treated with doses higher than 1.2 mg kg-' again the myelosuppressive effect of mitomycin C was seen in the first week after HAI only. However, 4 weeks after administration of the lethal dose the urea levels started to increase and the rats died within 10 days with 3-4 times normal urea levels. The rise in serum urea levels concurred with the onset of the second fall in weight (Figure la) . Severe weight loss resulting in increased protein catabolism could be responsible for this high urea level.
Macroscopic inspection at autopsy revealed no signs of the toxic side effects of mitomycin C as described by others: pulmonary toxicity (Gunstream et al., 1983) , cardiac toxicity (Levillain & Cluzan, 1973; Ganz et al., 1983) and renal toxicity (Cattell, 1985; Verweij, 1986) . Although the actual cause of death is unknown, rats treated with doses of mitomycin C higher than the maximally tolerated dose most probably were killed by delayed systemic toxicity.
The difference in toxicity pattern seen in ILP and HAI treated rats corresponded well with the differences in the concentrations measured in plasma and in liver tissue. Apparently there was minimal leakage from the isolated circuit to the systemic circulation, during and after perfusion, since the concentration of mitomycin C in plasma was significantly lower in the two ILP groups than in the HAI group. The liver tissue concentration in the rats treated with 1.2 mg kg-' was almost identical in the ILP and HAI groups and in both groups no sign of liver toxicity was observed. In contrast the much higher liver tissue concentration in the 4.8 mg kg' treated rats obviously was toxic to the liver.
In this study the ILP technique (Brauw et al., 1988) was extended with a cannula in the gastroduodenal artery as a second infusion limb in the perfusion circuit. This hepatic arterial infusion limb is essential since established liver metastases receive most of their blood supply from the hepatic artery (Ackerman, 1974; Izumi et al., 1986; Sigurdson et al., 1987) . Employing this ILP technique, with two inflow limbs in the perfusion circuit, the tumour tissue concentrations were at least as high as the liver tissue concentrations. This is remarkable since the tumour tissue is poorly vascularised compared with the liver tissue. In the ILP with 4.8 mg kg-' group the mean tissue concentrations in tumour were even much higher than in liver (t = 5 min, P < 0.05). A possible explanation for the relatively high tumour tissue concentrations could be a more rapid metabolism of mitomycin C in liver than in tumour tissue. The antitumour effect of ILP with mitomycin C is currently under investigation. Preliminary results indicate that ILP with the highest dose is very successful. Complete remissions are observed after ILP, but not after HAI (manuscript is in preparation). Schneider et al. (1989) demonstrated that mitomycin C is still a drug of interest for chemotherapeutic treatment of colorectal cancer. They conclude that intrahepatic mitomycin C has a definite salvage benefit in some patients with hepatic metastases from colorectal carcinoma previously treated with intrahepatic FUDR. We conclude that if in man, like in the rats in this study, hepatic metastases can be exposed to much higher doses of mitomycin C by ILP, this therapeutic option may be of clinical value. This study was supported by grant IKW 88-07 from the Dutch Cancer Foundation.
